

# **1 The cervical and meningeal lymphatic network as a pathway for**

## **2 retrograde nanoparticle transport to the brain**

3 Héctor M Ramos-Zaldívar<sup>1</sup>, Iva Polakovicova<sup>2,3</sup> †, Edison Salas-Huenuleo<sup>4</sup>, Claudia P Yeffi<sup>5</sup>,  
4 David Silva<sup>2,6</sup>, Pedro Jara-Guajardo<sup>2,6</sup>, Juan Esteban Oyarzún<sup>5,7</sup>, Álvaro Neira-Troncoso<sup>3,8</sup>,  
5 Patricia V. Burgos<sup>8</sup>, Viviana A. Cavieres<sup>8</sup>, Eloisa Arias-Muñoz<sup>8</sup>, Carlos Martínez<sup>9</sup>, Ana L.  
6 Riveros<sup>2,6</sup>, Alejandro H Corvalán<sup>2,3</sup>, Marcelo J Kogan<sup>2,6</sup>, Marcelo E Andia<sup>5,7</sup>

7 †: Deceased author

8 1. Doctoral Program in Medical Sciences, Faculty of Medicine, Pontificia Universidad Católica de Chile,  
9 Santiago, Chile.

10 2. Advanced Center for Chronic Diseases (ACCDiS), Santiago, Chile.

11 3. Department of Hematology and Oncology, Faculty of Medicine, Pontificia Universidad Católica de Chile.

12 4. Advanced Integrated Technologies SpA, (AINTECH), Santiago, Chile.

13 5. Millennium Institute for Intelligent Healthcare Engineering, Santiago, Chile.

14 6. Departamento de Química Farmacológica y Toxicológica, Facultad de Ciencias Químicas y Farmacéuticas,  
15 Laboratorio de Nanobiotecnología, Universidad de Chile, Carlos Lorca 964, Independencia, Chile

16 7. Biomedical Imaging Center, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.

17 8. Centro de Biología Celular y Biomedicina (CEBICEM), Facultad de Medicina y Ciencia, Universidad San  
18 Sebastián, Santiago, Chile.

19 9. Experimental Surgery and Simulation Center, Department of Digestive Surgery, Clinic Hospital, School of  
20 Medicine, Pontificia Universidad Católica de Chile, Marcoleta 377, Santiago, Chile.

22 Corresponding author: Héctor M. Ramos-Zaldívar

23 Contact information: Primary email: [hmramos@uc.cl](mailto:hmramos@uc.cl)

24

25

26

27 **Abstract**

28 **The meningeal lymphatic vessels have been described as a pathway that transports**  
29 **cerebrospinal fluid and interstitial fluid in a unidirectional manner towards the deep**  
30 **cervical lymph nodes. However, these vessels exhibit anatomical and molecular**  
31 **characteristics typical of initial lymphatic vessels, with the absence of surrounding**  
32 **smooth muscle and few or absent valves. Given its structure, this network could**  
33 **theoretically allow for bidirectional motion. Nevertheless, it has not been assessed as**  
34 **a potential route for nanoparticles to travel from peripheral tissues to the brain.**  
35 **Here we show that extracellular vesicles derived from the B16F10 melanoma cell**  
36 **line, along with superparamagnetic iron oxide nanoparticles, gold nanorods, and**  
37 **Chinese ink nanoparticles can reach the meningeal lymphatic vessels and the brain**  
38 **of C57BL/6 mice after administration within deep cervical lymph nodes *in vivo*,**  
39 **exclusively through lymphatic structures. Since the functional anatomy of dural**  
40 **lymphatics has been found to be conserved between mice and humans, we expect**  
41 **that our results will encourage further research into the retrograde motion of**  
42 **nanoparticles towards the brain for pharmacological purposes in nanomedicine, as**  
43 **well as to better understand the fluid dynamics in different physiological or**  
44 **neuropathological conditions.**

45

46 **Introduction**

47 The lymphatic system, including the meningeal lymphatic vessels, has usually been  
48 described as a unidirectional transport system of fluid and macromolecules from tissues

49 to venous circulation<sup>1,2</sup>. This concept has prevented its examination as a nanoparticle and  
50 drug delivery pathway to the brain, as administered contents would be expected to all be  
51 cleared to the thorax. Nevertheless, evaluating nanoparticle flow through these vessels is  
52 relevant considering the participation of the lymphatic system in immune transportation,  
53 its pathologic involvement in cancer metastasis and the spreading of some infectious  
54 diseases, as well as its potential as a drug delivery pathway for its targeting and  
55 pharmacokinetic advantages, including bypassing first-pass metabolism in the liver<sup>3</sup>.

56 Studies in mice have described the anatomical and morphological characteristics of  
57 meningeal lymphatics to be consistent with initial lymphatic vessels<sup>4,5</sup>. This includes a  
58 noncontinuous basement membrane, sparse or no lymphatic valves, and no smooth  
59 muscle cell lining<sup>4,5</sup>; which implies that meningeal lymphatic vessels might not have a  
60 preferential flow determined by its own structural components. Together, these findings  
61 open a theoretical possibility for retrograde flow towards the brain that would depend on  
62 the physiological and mechanical conditions of the vessels.

63 Here, we suggest that the cervical and meningeal lymphatic system can transport  
64 nanoparticles not only towards the thorax but can also serve to carry particles towards the  
65 brain.

66

67 **MRI imaging of SPIONs and SPION-loaded exosomes in cervical and**  
68 **meningeal lymphatic vessels**

69 Extracellular vesicles (EVs) are membranous particles naturally emitted by cells, encased  
70 in a lipid bilayer, and unable to undergo replication<sup>6</sup>. Exosomes are a subset of EVs that  
71 have an endosomal origin and a size range of 40 to 160 nm (average 100 nm)<sup>7</sup>. How EVs  
72 can travel between peripheral tissues and the brain in a bidirectional manner remains

73 poorly understood<sup>8</sup>. To investigate if the cervical and meningeal lymphatic system is a  
74 possible route for EVs crossing to and from the central nervous system (CNS), we  
75 prepared exosomes loaded with superparamagnetic iron oxide nanoparticles (SPIONs) to  
76 evaluate their anterograde and retrograde directional flow through MRI imaging,  
77 leveraging the high efficiency of SPIONs as contrast agents<sup>9</sup>. The anterograde directional  
78 flow was defined as the classically described motion of lymphatic components towards  
79 the thorax following an injection into the cisterna magna. The retrograde directional flow  
80 was defined as nanoparticle motion towards the meningeal lymphatic vessels and the  
81 brain after a deep cervical lymph node injection.

82 We first prepared SPIONs through coprecipitation of ferric and ferrous chlorides with  
83 ammonium associated with an acidic pH. This produced SPIONs with mean diameter of  
84  $14.28 \pm 5.57$  nm measured by dynamic light scattering (DLS) (Fig. 1a). Scanning  
85 transmission electron microscopy (STEM) confirmed SPIONs mean size of  $7.08 \pm 2.2$   
86 nm (Fig. 1a). The zeta potential was positive at  $36.9 \pm 0.51$  mV (Fig. 1a). After a ten-fold  
87 stock dilution with Milli-Q water, pH was increased to 7. Next, we proceeded to isolate  
88 exosomes from the B16F10 melanoma cell line using the Exo-spin (CELL GS) protocol.  
89 The MicroBCA (ThermoScientific) assay kit was used for total protein quantitation,  
90 yielding  $300 \mu\text{g/mL}$ . Western blot analysis confirmed the presence of EV markers EEA1  
91 and TSG101 (Fig. 1b). Finally, suspended exosomes were electroporated in 4 mm path  
92 length electroporation cuvettes. A single pulse was applied to each exosome sample under  
93 the high voltage setting and at an electric field of  $0.75 \text{ kV/cm}$ . After reisolating the labeled  
94 exosomes with Exo-spin columns, DLS revealed an exosome population of an average  
95 size of  $106 \text{ nm} \pm 27.35$  and a mean zeta potential of  $-17.1 \pm 0.53$  mV (Fig. 1c). Fig. 1c  
96 shows both B16F10 exosomes and exosomes electroporated with SPIONs as seen by  
97 electron microscopy.

98 To evaluate the retrograde directional flow through the cervical and meningeal lymphatic  
99 system, C57BL/6 mice (n=3 per condition) were injected *in vivo* with a 10  $\mu$ L solution of  
100 either SPIONs (3200  $\mu$ g/mL) or SPION-loaded exosomes ( $1.67 \times 10^{11}$  particles/mL).  
101 These were compared with control mice with no injections (n=3). Animals were  
102 anesthetized with 5% isoflurane for 5 min and kept under anesthesia with a nasal cannula  
103 supplying 1%-2% isoflurane during the entire procedure. A syringe with a 30G needle  
104 was loaded with 10  $\mu$ L of each solution and administered into the deep cervical lymph  
105 node. To locate the lymph node, skin and subcutaneous tissue were dissected at the  
106 midline of the neck, extending the field laterally at the supraclavicular area until both  
107 mandibular glands were exposed. Glands were detached from the clavicle surface and  
108 moved cranially. The sternocleidomastoid muscles were then displaced until the deep  
109 cervical nodes, surrounded by adipose tissue, were identified. Euthanasia by  
110 intraperitoneal sodium thiopental overdose (100 mg/kg) was performed 30 min after  
111 injection. The head and neck were preserved by fixation with 4% paraformaldehyde for  
112 MR imaging (Philips Achieva 1.5 T MR scanner) and histological analysis.

113 Both SPIONs and SPION-loaded exosomes revealed hypointense signals in the brain  
114 ventricles and parenchyma, particularly in the T2\* MRI maps (Fig. 2a). Hypointense  
115 signals were also detected at the level of the neck where the injections were administered.  
116 Retrograde directional flow of SPIONs injected into the deep cervical lymph node *in vivo*  
117 was observed in staining of neck and head lymphatic vessels, including meningeal  
118 lymphatics, in all mice (n=3) (Supplementary Fig. S1 and Supplementary Fig. S2c).  
119 However, no staining was observed within the brain parenchyma with the Perls' Prussian  
120 Blue technique. Iron detection through this staining method is prone to yield false  
121 negatives, as the detection requires the accumulation of several hundreds of nm in  
122 diameter<sup>10</sup>, which could hinder signals from SPIONs smaller than 10 nm diluted in the

123 volume of the brain parenchyma. Combined Perls' Prussian Blue staining and anti-  
124 LYVE-1 (lymphatic vessel endothelial hyaluronan receptor-1) immunohistochemistry  
125 revealed nanoparticles within the cervical lymphatic vessels towards the meningeal  
126 lymphatic vessels in the *in vivo* retrograde directional flow experiments performed on all  
127 C57BL/6 mice (n=3). No SPION staining was detected within arterial or venous  
128 structures within the head and neck (Supplementary Fig. S3b). As expected, exosomes  
129 loaded with SPIONS did not stain, indicating the presence of iron nanoparticles within  
130 exosome membranes.

131 To evaluate the anterograde directional flow, we injected C57BL/6 mice (n=3 per  
132 condition) *in vivo* with a 10  $\mu$ L solution of either SPIONS (3200  $\mu$ g/mL) or SPION-loaded  
133 exosomes (1.67  $\times$  10<sup>11</sup> particles/mL). These were compared with control mice with no  
134 injections. Animals were anesthetized with 5% isoflurane and kept under anesthesia with  
135 a nasal cannula supplying 1% isoflurane during the entire procedure. A syringe with a  
136 30G needle was loaded with 10  $\mu$ L of each solution and administered into the cisterna  
137 magna; by placing the mouse in prone position, flexing the head at a 135° angle with the  
138 body, and penetrating directly underneath and laterally to the end of the occipital bone  
139 towards the foramen magnum through the intact skin. Euthanasia by intraperitoneal  
140 sodium thiopental overdose (100 mg/kg) was performed 30 min after injection. The head  
141 and neck were preserved by fixation with 4% paraformaldehyde for 1.5 Tesla MRI  
142 scanner and histological analysis.

143 Both SPIONS and SPION-loaded exosomes showed hypointense signals of cervical  
144 lymphatic structures after intracerebroventricular injections through the cisterna magna,  
145 as seen in the T2w images and T2\* maps (Fig. 2b). Anterograde directional flow in *in*  
146 *vivo* procedures (n=3) of SPIONS after administration into the cisterna magna was

147 confirmed by the detection of Perls' Prussian Blue staining in cervical lymphatic vessels  
148 in all mice (Supplementary Fig. S4). At the level of the head, the injection into the cisterna  
149 magna also showed staining within the ventricles. As expected, exosomes loaded with  
150 SPIONs did not stain, indicating the presence of iron nanoparticles within exosome  
151 membranes.

152 Together, MRI imaging results indicate that the cervical and meningeal lymphatic system  
153 can transport SPIONs and SPION-labeled exosomes both towards the thorax and in the  
154 direction of the brain.

155

## 156 **Gold nanorods bidirectional motion through the cervical and meningeal** 157 **lymphatic system**

158 With MRI imaging suggesting the possibility of retrograde flow of SPIONs and SPION-  
159 loaded exosomes towards the brain after a cervical administration, we further examined  
160 other nanoparticles that could be more effectively assessed through histological  
161 techniques in the brain parenchyma. This also allowed the evaluation of different  
162 alternatives that can be subsequently explored in pharmacology and nanomedicine.  
163 Therefore, we used gold nanorods functionalized with polyethylene glycol (GNR-PEG)  
164 as described in Methods. GNR-PEG with a mean size of  $49.1 \pm 0.9$  nm and mean zeta  
165 potential of  $45 \pm 8$  mV were obtained and measured by DLS and Nanoparticle Tracking  
166 Analysis (NTA) (Fig. 1d). GNR-PEG morphology can be observed in the STEM image  
167 seen in Fig. 1d. The GNR-PEG size distribution determined by STEM showed a length  
168 of  $34.6 \pm 4.2$  nm and a width of  $11.4 \pm 1.6$  nm. The anterograde and retrograde directional  
169 flow were evaluated in two scenarios with *post-mortem* or *in vivo* administrations of

170 GNR-PEG solutions in C57BL/6 mice (n=3 per condition) into the cisterna magna or the  
171 deep cervical lymph node. These interventions were compared with control mice with no  
172 injections (n=3).

173 *Post-mortem* procedures were performed using 50  $\mu$ L of GNR-PEG at a concentration of  
174  $1.71 \times 10^{14}$  particles/mL. Dissections for identifying the deep cervical lymph node during  
175 retrograde administrations followed the method described previously for *in vivo*  
176 procedures. The head and neck were preserved by fixation with 4% paraformaldehyde for  
177 histological Gold Enhancement (Nanoprobes GoldEnhance TM LM Kit) analysis.

178 Retrograde directional flow in *post-mortem* procedures (n=3) of gold nanorods after deep  
179 cervical lymph node administration was confirmed by the detection of Gold Enhancement  
180 staining at different CNS regions in all mice. These included the olfactory bulb, the brain  
181 parenchyma, and within the meningeal lymphatic vessels (Fig. 3a). No staining was  
182 detected within arterial or venous structures within the head and neck, ruling out other  
183 sources of nanoparticle distribution to the brain in *post-mortem* GNR-PEG assays.  
184 Control mice with no GNR-PEG administrations showed no Gold Enhancement staining  
185 in any anatomical structure.

186 Anterograde directional flow in *post-mortem* procedures (n=3) of GNR-PEG after  
187 administration into the cisterna magna was also confirmed by the detection of Gold  
188 Enhancement staining in cervical lymphatic vessels in all mice, as well as in the  
189 connective tissue of the neck (Fig. 5a). Gold nanoparticles were also identified in the  
190 cervical spinal cord as well as its surrounding subdural space and associated peripheral  
191 nerves (Fig. 5a). At the level of the head, the injection into the cisterna magna also showed  
192 staining within lateral ventricles, the third ventricle, the olfactory bulb, and the optic  
193 chiasm in all mice. No Gold Enhancement staining was observed in any anatomical  
194 structure of the control mice that did not receive GNR-PEG administrations.

195 To investigate the directional flow of GNR-PEG under physiological conditions and to  
196 minimize the potential impact of volume, we administered 10  $\mu$ L of GNR-PEG at a  
197 concentration of  $1.71 \times 10^{14}$  particles/mL *in vivo*. The administration technique was as  
198 previously described for deep cervical lymph node and cisterna magna injections.  
199 Combined Gold Enhancement and anti-LYVE-1 immunohistochemistry revealed gold  
200 nanoparticles within the cervical and meningeal lymphatic vessels in the *in vivo*  
201 retrograde directional flow experiments performed on all C57BL/6 mice (n=3) (Fig. 4a).  
202 GNR-PEG also reached the brain parenchyma through the retrograde flow from the  
203 cervical lymphatic vessels in all mice (Fig. 4a). GNR-PEG were found staining within  
204 anti-LYVE1 cervical lymphatic vessels towards the meningeal lymphatics  
205 (Supplementary Fig. S2a). No staining was detected within arterial or venous structures  
206 within the head and neck, ruling out other sources of nanoparticle distribution to the brain  
207 in *in vivo* gold nanoparticle assays (Supplementary Fig. S3a). Anterograde directional  
208 flow of gold nanoparticles after administration into the cisterna magna *in vivo* was  
209 established by the detection of Gold Enhancement staining in cervical lymphatic vessels  
210 in all mice (Fig. 6a). Gold Enhancement staining was not detected in any anatomical  
211 structure of the control mice that did not undergo GNR-PEG administrations.  
212 The results of histological analyses collectively suggest that the cervical and meningeal  
213 lymphatic system is capable of bidirectional transportation of gold nanorods,  
214 encompassing movement towards both the thorax and the brain.

215

216 **Chinese ink bidirectional motion through the cervical and meningeal**  
217 **lymphatic system**

218 Chinese ink has been previously used for staining of lymphatic structures<sup>11-13</sup>, which led  
219 to its consideration for our evaluation on the bidirectional motion of nanoparticles through  
220 the cervical and meningeal lymphatic system. Interestingly, Chinese ink (Artel, Santiago,  
221 Chile) was characterized by DLS, which revealed nanoparticles with a mean ( $\pm$  SD) size  
222 of  $61.62 \pm 4.84$  nm and mean ( $\pm$  SD) surface zeta potential of  $-6.34 \pm 0.63$  mV (Fig. 1e),  
223 which are measurements similar to the range values observed in purified exosomes. To  
224 our surprise, we found that Chinese ink can also be stained with the Gold Enhancement  
225 technique (Nanoprobes GoldEnhance TM LM Kit) used previously with GNR, confirmed  
226 by the lack of staining of control mice brain parenchyma slides with no nanoparticle  
227 administration. The anterograde and retrograde directional flow were evaluated after  
228 *post-mortem* and *in vivo* administrations of Chinese ink solutions in C57BL/6 mice (n=3  
229 per condition) in the cisterna magna and the deep cervical lymph node, respectively.  
230 These were compared with control mice with no injections (n=3).

231 *Post-mortem* procedures were performed using 50  $\mu$ L of 10% Chinese ink (Artel,  
232 Santiago, Chile). Dissections for identifying the deep cervical lymph node during  
233 retrograde administrations followed the method described previously for procedures with  
234 SPION-loaded exosomes. The head and neck were preserved by fixation with 4%  
235 paraformaldehyde for histological Gold Enhancement (Nanoprobes GoldEnhance TM  
236 LM Kit) analysis. Retrograde directional flow in *post-mortem* procedures (n=3) of  
237 Chinese ink after deep cervical lymph node administration was confirmed by the  
238 detection of Gold Enhancement staining at different CNS regions in all mice (Fig. 3b).  
239 Staining was detected within the meningeal lymphatic vessels, the third ventricle, and  
240 cortical regions near meningeal lymphatic vessels. No staining was detected within  
241 arterial or venous structures within the head and neck, ruling out other sources of  
242 nanoparticle distribution to the brain in *post-mortem* Chinese ink assays. In control mice

243 that did not undergo Chinese ink administrations, there was no presence of Gold  
244 Enhancement staining in any anatomical structure.

245 Anterograde directional flow in post-mortem procedures (n=3) of Chinese ink  
246 nanoparticles after administration into the cisterna magna was confirmed by the detection  
247 of staining in cervical lymphatic vessels in all mice, as well as in connective tissue of the  
248 neck (Fig. 5b). Chinese ink nanoparticles were also identified in the cervical spinal cord  
249 as well as its surrounding subdural space (Fig. 5b). At the level of the head, the injection  
250 into the cisterna magna also showed staining within lateral ventricles. The anatomical  
251 structures of the control mice that did not receive Chinese ink administrations exhibited  
252 no signs of Gold Enhancement staining.

253 To examine the Chinese ink directional flow under physiological conditions and reducing  
254 the potential effects of volume, we conducted *in vivo* administrations of 10  $\mu$ L of 10%  
255 Chinese ink (Artel, Santiago de Chile). The administration procedure followed the  
256 previously established method for injections into the deep cervical lymph nodes and the  
257 cisterna magna. Retrograde directional flow of *in vivo* procedures (n=4) was confirmed  
258 in all mice after deep cervical lymph node administration. Combined Gold Enhancement  
259 and anti-LYVE-1 immunohistochemistry showed Chinese ink within the meningeal  
260 lymphatic vessels and cortical regions near these lymphatic structures (Fig. 4b). One  
261 mouse died at minute two before the expected completion time of 30 min before  
262 euthanasia. Nevertheless, after histological analysis of this specimen, Chinese ink  
263 nanoparticles were identified in the meningeal lymphatic vessels and the brain  
264 parenchyma. Chinese ink was found staining within anti-LYVE1 cervical lymphatic  
265 vessels towards the meningeal lymphatics (Supplementary Fig. S2b). No staining was  
266 detected within arterial or venous structures within the head and neck of two out of three  
267 mice (Supplementary Fig. S3c). One mouse presented staining within the jugular vein but

268 not the carotid artery (Supplementary Fig. S3), which also indicates that the observed  
269 nanoparticles at the meningeal lymphatic vessels and the brain parenchyma originate  
270 mainly from the lymphatic system distribution and not through arterial circulation of  
271 cardiac and other thoracic vessels. Anterograde directional flow in *in vivo* procedures  
272 (n=3) after administration into the cisterna magna was confirmed by the detection of  
273 staining in cervical lymphatic vessels in all mice (Fig. 6b). Chinese ink nanoparticles were  
274 also identified in the subarachnoid space, the cervical spinal cord, and peripheral nerves  
275 (Fig. 6b). No staining was observed in any anatomical structure of the control mice that  
276 did not receive any administrations.

277 Taken together, the findings of histological analyses indicate that the cervical and  
278 meningeal lymphatic system is capable of bidirectional transportation of Chinese ink  
279 nanoparticles, involving movement towards both the thorax and the brain.

280

## 281 **Discussion**

282 We have shown evidence that suggests that the cervical and meningeal lymphatic system  
283 can transport nanoparticles not only in the classically described lymphatic drainage  
284 towards the thorax but can also serve as an access gate to the brain. SPIONs and SPION-  
285 loaded exosomes were detected by MRI in the brain of C57BL/6 mice after deep cervical  
286 lymph node administration *in vivo*. Gold nanorods and Chinese ink nanoparticles were  
287 also identified within the meningeal lymphatic vessels and the brain parenchyma of mice  
288 in the retrograde directional flow histological analysis from cervical injections in *post-*  
289 *mortem* and *in vivo* procedures. Anterograde directional flow experiments from all  
290 nanoparticle experiments also showed motion from the cisterna magna to the deep

291 cervical lymph nodes. Together, these indicate that the system allows for bidirectional  
292 flow after administration.

293 Two pertinent factors to examine regarding this newly described retrograde lymphatic  
294 flow towards the brain include alternative vascular pathways and the influence of pressure  
295 exerted at the cervical injection site. The initial consideration, particularly in *in vivo*  
296 assays, was whether nanoparticles in meningeal lymphatic vessels and the brain might  
297 have originated from their distribution from the cervical lymphatic vessels, passing  
298 through the jugular vein, the superior vena cava, the right atrium and ventricle of the  
299 heart, through the pulmonary circulation, to the left atrium and ventricle of the heart, and  
300 towards the carotid arteries before entering the cerebral circulation. This would entail that  
301 nanoparticles would have been present in histological analyses within the jugular veins  
302 and the common carotid arteries during cervical examinations. However, as previously  
303 indicated, all *in vivo* SPION, GNR-PEG, and Chinese ink retrograde experiments  
304 (collectively n=10) showed no staining of carotid arteries. Moreover, nine out of the ten  
305 deep cervical lymphatic nanoparticle administrations showed no staining of jugular veins.  
306 GNR-PEG and Chinese ink post-mortem retrograde injections (collectively n=6) also  
307 concurred with these findings. Given that nanoparticles were indeed found staining within  
308 anti-LYVE1 cervical lymphatic vessels towards the meningeal lymphatics, this data  
309 supports the conclusion that nanoparticles reaching the brain were following a lymphatic  
310 pathway.

311 It is important to consider that although the volume injected in *in vivo* procedures was  
312 small (10  $\mu$ L) the pressure exerted at the cervical injection site could have been  
313 significantly greater than the intranodal pressure, changing the fluid dynamics within the  
314 lymph node. However, this relationship is complex to determine at this stage because  
315 cervical intranodal pressures have not yet been established. Previous studies have

316 analyzed intranodal pressure of other anatomical locations in mice with different results.

317 Bouda *et al.* described intranodal popliteal and axillary pressures of an average 9 and 12  
318 cmH<sub>2</sub>O, respectively, in normal wild type mice<sup>14</sup>. Kato *et al.* and Miura *et al.* used  
319 MXH10/Mo-lpr/lpr, a mouse model that develops systemic swelling of lymph nodes,  
320 obtaining lower values for intranodal pressures<sup>15,16</sup>. Miura *et al.* showed that mean  
321 pressures within subiliac and axillary nodes were 0.10 cm H<sub>2</sub>O and 0.03 cm H<sub>2</sub>O,  
322 respectively<sup>16</sup>. When examining their data, Kato *et al.* found subiliac lymph nodes with a  
323 mean pressure of 1.63 cm H<sub>2</sub>O<sup>15</sup>. Finally, Rhoner *et al.* have even described  
324 subatmospheric pressures of -1 cm H<sub>2</sub>O in axillary and brachial lymph nodes of immune-  
325 competent C57Bl/6 mice<sup>17</sup>.

326 Another factor to consider is that the pressure that can be produced for any syringe at a  
327 predetermined speed depends on the force applied divided by the surface area of the  
328 syringe plunger<sup>18</sup>. While humans can apply considerable forces to a plunger, with an  
329 average maximum force of 79N, this implies that a lower injection force is needed to  
330 generate equivalent pressures when syringe caliber is reduced<sup>18</sup>. Therefore, injections  
331 performed by a human operator may differ considerably in force and pressure exerted  
332 depending on the syringe caliber and intranodal state. Future research should address  
333 cervical intranodal pressures and the biomechanics of fluid administration to better  
334 understand the fluid dynamics of this anatomical region.

335 It should be highlighted that mice and human functional anatomy of dural lymphatics has  
336 been found to be conserved. Jacob *et al.* found similar circa-cerebral meningeal lymphatic  
337 architecture and relationship with dural venous sinuses, with limited connections with the  
338 nasal lymphatic bed, and a conserved pattern of cavernous sinus associated vessels  
339 penetrating the skull through several bilateral foramina of the skull base<sup>19</sup>. They  
340 emphasized that murine models are relevant to predict the pathophysiological

341 contribution of the dural lymphatic system and test lymphatic-targeted drugs in  
342 neurological disease models<sup>19</sup>. Here we evaluated different nanoparticles with  
343 pharmacological applications through these lymphatic vessels and point to a bidirectional  
344 potential that opens the possibility of a new access to the brain. Our experiments therefore  
345 can also give insights into possible human fluid dynamics that should be explored.

346 The exact drivers of this bidirectional flow could involve pressure changes within the  
347 lymphatic vessels and nodes in a system with few valves and no smooth muscle cell lining  
348 when entering the head. This means that anatomical position changes or physiological  
349 changes in pressure surrounding lymphatic tissues could create conditions favoring  
350 motion in the retrograde or anterograde flow when necessary. Pathological conditions  
351 producing pressure changes in or around lymphatic tissues could also promote and  
352 determine directional flow in the cervical and meningeal lymphatic system. Particularly  
353 in mammals such as humans that experience radical changes in head and neck dynamics  
354 with the upright and recumbent position, the possibility of bidirectional lymphatic flow  
355 could be relevant in many physiological processes such as during sleep.

356 The pharmacological implications of our findings could be important in the field of  
357 nanomedicine. The methodology used for labeling exosomes in this project could be  
358 modified to carry drugs through the lymphatic system and improve specific distribution  
359 to the brain. Further studies can evaluate if an interstitial injection in the neck could  
360 deliver enough nanoparticles through this system to develop noninvasive treatment  
361 procedures, as homing characteristics to lymph nodes have been seen in previous studies  
362 of SPION-loaded exosomes to popliteal lymphatics<sup>20</sup>. Given that cancer exosomes could  
363 potentially move towards the brain through this pathway, and that an anecdotal case report  
364 has suggested that cancer cells can move in a retrograde lymphatic manner in other organs  
365 even in valve-equipped lymphatic vessels<sup>21</sup>, mortality in these patients would be

366 substantially reduced if cerebral metastatic mechanisms could be prevented. In this  
367 regard, future investigations can delve into cancer exosome lymphatic inhibitors, by  
368 regulating or blocking movement through these vessels.

369 In neurodegenerative diseases, the use of promising peptide inhibitors of polyglutamine  
370 aggregation (QBP1, NT17, and PGQ9P2) in Huntington's disease has been hindered  
371 precisely because of poor BBB penetration and low bioavailability<sup>22</sup>. A cervical  
372 lymphatic route could be an attractive pathway to evaluate more efficient means for  
373 accessing the brain without complex nanoparticle constructions. A recent publication by  
374 Dominy et al. has associated *P. gingivalis* with Alzheimer's disease<sup>23</sup>. Bacterial DNA and  
375 RNA found in the brain of patients with this disease could be transported by exosomes  
376 through the lymphatic system. Other rapidly rising fields, such as the connection between  
377 the gut microbiota with diseases such as autism, neurological disorders like multiple  
378 sclerosis, and mental disorders<sup>24</sup>, could potentially involve retrograde lymphatic flow of  
379 exosomes and different nanoparticles towards the brain.

380 In conclusion, the cervical and meningeal lymphatic system can serve as an access route  
381 for nanoparticles to the brain, allowing bidirectional flow. This newly discovered  
382 mechanism for the meningeal lymphatic pathway could be exploited in the theranostic  
383 field of nanomedicine to deliver drugs for the treatment of various neurological diseases.  
384 Additionally, our findings using exosomes from the metastatic B16F10 melanoma cell  
385 line could aid in a more profound comprehension of brain metastasis pathophysiology  
386 regarding the participation of extracellular vesicles.

387

388 **Methods**

389 **Superparamagnetic iron oxide nanoparticle synthesis**

390 Samples of iron oxide nanoparticles were prepared by a chemical coprecipitation process  
391 from  $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$  (432 mg), and  $\text{FeCl}_2 \cdot 4\text{H}_2\text{O}$  (159mg). Ferric and ferrous chlorides  
392 were dissolved in 19mL of Milli-Q water with vigorous magnetic agitation at room  
393 temperature. One mL of ammonium (25%) was added to the solution with vigorous  
394 magnetic agitation for 10 min. Then, three washes with Milli-Q water were performed,  
395 maintaining iron-nanoparticles in an 80 mL beaker with a neodymium magnet.  
396 Subsequently, the superparamagnetic iron oxide nanoparticles were washed twice with  
397 nitric acid. Finally, iron-nanoparticles were dissolved in Milli-Q water for later  
398 characterization. A ten-fold stock dilution with Milli-Q water increased pH to 7.

399 **Characterization of iron oxide nanoparticles**

400 The morphology and particle size of SPIONs was investigated by scanning transmission  
401 electron microscopy (STEM, FEI Quanta 250) operating at 10.00 kV. The Malvern  
402 Zetasizer was used for dynamic light scattering size determination and superficial charge.  
403 SPIONs concentrations obtained from the synthesis were measured using Nanoparticle  
404 Tracking Analysis by NanoSight. pH of the solutions was determined by pH meter. The  
405 concentration of iron nanoparticles in solutions was determined by inductively coupled  
406 plasma mass spectrometry (ICP MS).

407 **Cell culture and exosome purification**

408 The B16F10 melanoma cell line was cultured using Exo-free medium. The isolated  
409 supernatant was centrifuged twice: first at 300g for 10 min at 4 °C and then at 16000g for  
410 20 min at 4 °C. Filtration followed through 0.2  $\mu\text{m}$  pore size filters. For purification, an  
411 Exo-spin (CELL GS) protocol was conducted. Extracellular vesicles were first

412 concentrated using a 10 kDa filter to separate larger cellular structures and then diluted  
413 in filtered PBS (0.1  $\mu$ m pore size). The samples were then precipitated using Exo-spin  
414 Buffer overnight and then centrifuged for 1 hour at 16000g. The obtained pellet with  
415 exosomes was resuspended in 100  $\mu$ L of PBS. Exo-spin columns were prepared with two  
416 consecutive washes with 250  $\mu$ L of PBS at 50g for 10 sec. Finally, diluted exosomes were  
417 passed through the column using 200  $\mu$ L of PBS and collected in microcentrifuge tubes.

418 **Nanoparticle internalization to exosomes**

419 Suspended exosomes, purified as previously described, were electroporated in 4 mm path  
420 length electroporation cuvettes. A single pulse was applied to each exosome sample under  
421 the high voltage setting and at an electric field of 0.75 kV/cm. Following electroporation,  
422 nanoparticle-loaded exosomes were reisolated using the Exo-spin protocol.

423 **Characterization of exosomes**

424 Exosomes were characterized by protein concentration (microBCA assay), shape by  
425 scanning transmission electron microscopy (STEM, FEI Quanta 250), concentration and  
426 size with NanoSight. Western blot analysis was performed to determine the presence of  
427 exosome markers EEA1 and TSG101. Cell extracts and exosomes were lysed at 4°C in  
428 lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100)  
429 supplemented with a cocktail of protease inhibitors [416  $\mu$ M 4-(2-  
430 Aminoethyl)benzenesulfonyl fluoride, 0.32  $\mu$ M Aprotinin, 16  $\mu$ M Bestatin, 5.6  $\mu$ M E-64,  
431 8  $\mu$ M Leupeptin and 6  $\mu$ M Pepstatin A; Sigma-Aldrich] and phosphatase inhibitors (1  
432 mM NaF, 0,3 mM Na2P2O7 and 1 mM Na3VO4; Sigma-Aldrich). Cell lysates were  
433 collected and lysed for 30 min at 4°C in rotation. Extracts were further centrifuged for 20  
434 min at 13.000xg at 4°C. Samples with an equivalent amount of protein were denatured at  
435 65°C for 5 min with Laemmli SDS- PAGE sample buffer and analyzed by SDS-PAGE.

436 **Gold nanorods synthesis**

437 For the preparation of a seed solution of gold nanoparticles, a cold-prepared sodium  
438 borohydride solution (600  $\mu$ L, 0.01 M) was added to 250  $\mu$ L of 0.01 M HAuCl<sub>4</sub> in 9.75  
439 mL of 0.1 M cetyltrimethylammonium bromide (CTAB) in a flask, under vigorous  
440 magnetic stirring. The seed solution was kept at 27 °C for 2 h, before use. After that, 55  
441  $\mu$ L of 0.1 M ascorbic acid solution (Sigma Chemical Co., St. Louis, MO, USA) was added  
442 to a growth solution containing 75  $\mu$ L of 0.01 M AgNO<sub>3</sub> (Sigma Chemical Co., St. Louis,  
443 MO, USA), 9.5 mL of 0.1 M CTAB, and 500  $\mu$ L of 0.01 M HAuCl<sub>4</sub>. Further, 250  $\mu$ L of  
444 0.1 M HCl and 12  $\mu$ L of the previously prepared seed solution were added. The solution  
445 was incubated for 10 min at 27 °C and then centrifuged at a 7030g for 15 min. After  
446 centrifugation, the supernatant was removed, and the pellet was resuspended in milli-Q  
447 water.

448 The GNRs were conjugated with asymmetrical PEGs that have a thiol group (SH) at one  
449 end, and a methoxy (HS-PEG-OMe MW 5K, JenKem Technology, TX, USA) or a  
450 carboxylic acid group (HS-PEG-COOH MW 5K, JenKem Technology, TX, USA) at the  
451 other. A total of 50  $\mu$ L of 1 mM HS-PEG-OMe in a water solution was added to 10 mL  
452 of 1 nM GNRs-CTAB and stirred for 10 min. After centrifugation at RCF of 16,100g for  
453 10 min, the pellet was resuspended in 10 mL of milli-Q water. Subsequently, 300  $\mu$ L of  
454 1 mM HS-PEG-COOH solution was added into the water solution, and the suspension  
455 obtained was stirred for one hour. Further, the suspension was centrifuged at 16,100g for  
456 10 min, and the pellet was resuspended in 100  $\mu$ L of 0.1 M 2-(N-  
457 morpholino)ethanesulfonic acid (MES) buffer pH 5.5. Subsequently, 0.2 mg of ethyl-3-  
458 (3-dimethylaminopropyl)-carbodiimide (EDC) and 0.5 mg of sulfo-N-  
459 hydroxysuccinimide (Sulfo-NHS) in 100  $\mu$ L of MES were added and mixed for 15 min.

460 The excess of EDC/Sulfo-NHS was subsequently removed by centrifugation at 16,100g  
461 for 10 min. The resulting pellet was dissolved in phosphate buffered saline (PBS) pH 7.4.  
462 The final solution was stirred overnight and centrifuged again the next day, at 16,100× g  
463 for 10 min. Then, the pellet was resuspended in milli-Q water and stored at 4 °C.

464 **Characterization of gold nanorods and Chinese ink**

465 The morphology and particle size of SPIONs was investigated by scanning transmission  
466 electron microscopy (STEM, FEI Quanta 250) operating at 10.00 kV. Dynamic light  
467 scattering system for nanoparticle analysis was used for size determination. The  
468 superficial charge was measured by a Zeta Potential Analyzer. Concentrations obtained  
469 from the synthesis were measured using Nanoparticle Tracking Analysis by NanoSight.  
470 Chinese ink was obtained from commercially available ARTEL and used at a  
471 concentration of 10%.

472 **Experimental design for retrograde and anterograde directional flow evaluation in  
473 mice**

474 For *post-mortem* anterograde evaluations different nanoparticle solutions (gold nanorods  
475 and Chinese ink) were injected into the cisterna magna of C57BL/6 mice (n=3 per  
476 condition), after euthanasia by ketamine (300mg/kg) and xylazine (30 mg/kg) overdose.  
477 These were compared with control mice with no injections (n=3). A syringe with a 30G  
478 needle was loaded with 50 µL of each solution and administered in the cisterna magna;  
479 by placing the mouse in prone position, flexing the head at a 135° angle with the body,  
480 and penetrating directly underneath and laterally to the end of the occipital bone towards  
481 the foramen magnum through the intact skin. The head and neck were preserved by  
482 fixation with 4% paraformaldehyde for histological Gold Enhancement (Nanoprobes  
483 GoldEnhance TM LM Kit) analysis.

484 For *post-mortem* retrograde flow evaluation different nanoparticle solutions (gold  
485 nanorods and Chinese ink) were injected into the deep cervical lymph node of C57BL/6  
486 mice (n=3 per condition), after euthanasia by intraperitoneal ketamine (300mg/kg) and  
487 xylazine (30 mg/kg) overdose. These were compared with control mice with no injections  
488 (n=3). A syringe with a 30G needle was loaded with 50  $\mu$ L of each solution and  
489 administered into the deep cervical lymph node. To locate the lymph node, skin and  
490 subcutaneous tissue were dissected at the midline of the neck, extending the field laterally  
491 at the supraclavicular area until both mandibular glands were exposed. Glands were  
492 detached from the clavicle surface and moved cranially. The sternocleidomastoid muscles  
493 were then displaced until the deep cervical nodes, surrounded by adipose tissue, were  
494 identified. The head and neck were preserved by fixation with 4% paraformaldehyde for  
495 histological Gold Enhancement (Nanoprobes GoldEnhance TM LM Kit) analysis.

496 For *in vivo* anterograde flow evaluation different nanoparticle solutions (SPIONs,  
497 exosomes loaded with SPIONs, gold nanorods, and Chinese ink) were injected into the  
498 cisterna magna of C57BL/6 mice (n=3 per condition). These were compared with control  
499 mice with no injections (n=3). Animals were anesthetized with 5% isoflurane and kept  
500 under anesthesia with a nasal cannula supplying 1% isoflurane during the entire  
501 procedure. A syringe with a 30G needle was loaded with 10  $\mu$ L of each solution and  
502 administered in the cisterna magna; by placing the mouse in prone position, flexing the  
503 head at a 135<sup>0</sup> angle with the body, and penetrating directly underneath and laterally to  
504 the end of the occipital bone towards the foramen magnum through the intact skin.  
505 Euthanasia by intraperitoneal sodium thiopental overdose (100 mg/kg) was performed 30  
506 min after injection. The head and neck were preserved by fixation with 4%  
507 paraformaldehyde for MRI and histological analysis.

508 For *in vivo* retrograde flow evaluation different nanoparticle solutions (SPIONs,  
509 exosomes loaded with SPIONs, gold nanorods, and Chinese ink) were injected into the  
510 deep cervical lymph node of C57BL/6 mice (n=3 per condition; Chinese ink n=4). These  
511 were compared with control mice with no injections (n=3). Animals were anesthetized  
512 with 5% isoflurane and kept under anesthesia with a nasal cannula supplying 1%  
513 isoflurane during the entire procedure. A syringe with a 30G needle was loaded with 10  
514  $\mu$ L of each solution and administered into the deep cervical lymph node. To locate the  
515 lymph node, skin and subcutaneous tissue were dissected at the midline of the neck,  
516 extending the field laterally at the supraclavicular area until both mandibular glands were  
517 exposed. Glands were detached from the clavicle surface and moved cranially. The  
518 sternocleidomastoid muscles were then displaced until the deep cervical nodes,  
519 surrounded by adipose tissue, were identified. Euthanasia by intraperitoneal sodium  
520 thiopental overdose (100 mg/kg) was performed 30 min after injection. The head and  
521 neck were preserved by fixation with 4% paraformaldehyde for MRI and histological  
522 analysis.

523 The image acquisition was performed with a clinical Philips Achieva 1.5T MR scanner  
524 (Philips Healthcare, Best, Netherlands) and a single-loop surface coil (diameter=47 mm).  
525 Perls' Prussian blue was used for iron tissular content analysis. Gold Enhancement  
526 (Nanoprobes GoldEnhance TM LM Kit) was used for GNR and Chinese ink analysis.

527 **Formalin-fixed, paraffin-embedded (FFPE) tissue processing for histology and  
528 special stains**

529 Whole brain and neck samples were fixed for 24 hours on 4% PFA and then processed  
530 for paraffin embedding. Coronal sections of 4  $\mu$ m were cut from each paraffin block, then  
531 sections were dried, deparaffinized and re-hydrated on distilled water. Gold Enhancement

532 was performed with Nanoprobes GoldEnhance TM LM Kit according to manufacturer's  
533 instructions. Once this procedure was done, the sections were counterstained with eosin.  
534 Nanoparticles were illustrated by Perls' Prussian blue staining for iron content<sup>25</sup>. Tissue  
535 was deparaffinized and hydrated with distilled water, immersed in 10% aqueous  
536 potassium ferrocyanide and 20% aqueous hydrochloric acid for 20 min. Images of the  
537 stained slides were taken with an ICC50W Camera on a DM500 Leica Microscope at 4x,  
538 10x, 20x, and 40x magnification.

539 Immunohistochemistry analysis was performed on the different sections with joint  
540 staining with Gold Enhancement and Perls' Prussian blue to evaluate colocalization with  
541 an endothelial marker of lymphatic vessels (LYVE-1). After deparaffinization, antigen  
542 recovery was done using buffer Tris-EDTA pH 9.0 in a pressure cooker for 20 min.  
543 Endogenous peroxidase was blocked with 3% hydrogen peroxide for 15 min. Blocking  
544 of non-specific binding was performed with 3% BSA/PBS for 30 min. Overnight  
545 incubation at 4°C with the primary antibody, Recombinant Anti-LYVE1 antibody  
546 [EPR21771] (ab218535), was done at 1:5000 dilution. This was followed by incubation  
547 with the secondary antibody, Goat Anti-Rabbit IgG H&L (HRP) ab6721 (Abcam), for 1  
548 hour at 25°C. Each slide was then developed with DAB for 1 min. Lung, gall bladder,  
549 and spleen tissues were used as controls. Quantification of histological images were  
550 performed with the software Image J.

## 551 **Animals**

552 All procedures complied with regulations of the Research Ethics Committee of the  
553 Pontificia Universidad Católica de Chile. 49 Male C57BL/6 mice were purchased from  
554 the animal facility of the Pontificia Universidad Católica de Chile and housed in  
555 temperature and humidity-controlled rooms, maintained on a 12h/12h light/dark cycle.

556 Only adult animals (eight to ten weeks) were used in this study. Nine animals were  
557 assigned to *post-mortem* anterograde directional flow experiments, nine to *post-mortem*  
558 retrograde directional flow analyses, 15 to *in vivo* anterograde directional flow  
559 experiments, and 16 to the *in vivo* retrograde directional flow group. The sample size was  
560 chosen following similar, previously published research <sup>4,20,26,27</sup>. Animals from different  
561 cages in the same experimental group were selected to assure randomization.

562 **Ethical approval**

563 All experimental protocols were approved by the Research Ethics Committee of the  
564 Pontificia Universidad Católica de Chile, the CEC-CAA (Comité Ético Científico para el  
565 Cuidado de Animales y Ambiente), with Protocol ID: 190826005. This study was  
566 conducted according to ARRIVE guidelines.

567

568 **References**

- 569 1. Hershenhouse, K. S., Shauly, O., Gould, D. J. & Patel, K. M. Meningeal Lymphatics: A  
570 Review and Future Directions From a Clinical Perspective. *Neurosci Insights* **14**,  
571 1179069519889027 (2019).
- 572 2. Jiang, H. *et al.* Overview of the meningeal lymphatic vessels in aging and central  
573 nervous system disorders. *Cell Biosci* **12**, 202 (2022).
- 574 3. Ali Khan, A., Mudassir, J., Mohtar, N. & Darwis, Y. Advanced drug delivery to the  
575 lymphatic system: lipid-based nanoformulations. *Int J Nanomedicine* **8**, 2733–2744  
576 (2013).
- 577 4. Louveau, A. *et al.* Structural and functional features of central nervous system  
578 lymphatic vessels. *Nature* **523**, 337–341 (2015).
- 579 5. Aspelund, A. *et al.* A dural lymphatic vascular system that drains brain interstitial fluid  
580 and macromolecules. *J Exp Med* **212**, 991–999 (2015).
- 581 6. Théry, C. *et al.* Minimal information for studies of extracellular vesicles 2018  
582 (MISEV2018): a position statement of the International Society for Extracellular Vesicles  
583 and update of the MISEV2014 guidelines. *J Extracell Vesicles* **7**, (2018).

584 7. Kalluri, R. & LeBleu, V. S. The biology, function, and biomedical applications of  
585 exosomes. *Science* **367**, (2020).

586 8. Ramos-Zaldívar, H. M. *et al.* Extracellular vesicles through the blood-brain barrier: a  
587 review. *Fluids Barriers CNS* **19**, 60 (2022).

588 9. Vangijzegem, T. *et al.* Superparamagnetic Iron Oxide Nanoparticles (SPION): From  
589 Fundamentals to State-of-the-Art Innovative Applications for Cancer Therapy.  
590 *Pharmaceutics* **15**, (2023).

591 10. Curdt, F. *et al.* Prussian blue technique is prone to yield false negative results in  
592 magnetoreception research. *Sci Rep* **12**, 8803 (2022).

593 11. CAO, Q., WANG, S., XU, K., LIU, X. & LIU, L. Experimental Study of Chinese Ink as a New  
594 Type of Dye Tracer in Sentinel Lymph Node Biopsy. *The Chinese-German Journal of*  
595 *Clinical Oncology* **5**, 36–39 (2006).

596 12. Mori, K. Identification of lymphatic vessels after intra-arterial injection of dyes and  
597 other substances. *Microvasc Res* **1**, 268–274 (1969).

598 13. Kato, S., Shirai, Y., Sakamoto, M., Mori, S. & Kodama, T. Use of a Lymphatic Drug  
599 Delivery System and Sonoporation to Target Malignant Metastatic Breast Cancer Cells  
600 Proliferating in the Marginal Sinuses. *Sci Rep* **9**, 13242 (2019).

601 14. Bauta, E. M. *et al.* Measuring intranodal pressure and lymph viscosity to elucidate  
602 mechanisms of arthritic flare and therapeutic outcomes. *Ann N Y Acad Sci* **1240**, 47–52  
603 (2011).

604 15. Kato, S. *et al.* Intranodal pressure of a metastatic lymph node reflects the response to  
605 lymphatic drug delivery system. *Cancer Sci* **111**, 4232–4241 (2020).

606 16. Miura, Y. *et al.* Early diagnosis of lymph node metastasis: Importance of intranodal  
607 pressures. *Cancer Sci* **107**, 224–232 (2016).

608 17. Rohner, N. A. *et al.* Lymph node biophysical remodeling is associated with melanoma  
609 lymphatic drainage. *FASEB J* **29**, 4512–4522 (2015).

610 18. Vo, A., Doumit, M. & Rockwell, G. The Biomechanics and Optimization of the Needle-  
611 Syringe System for Injecting Triamcinolone Acetonide into Keloids. *J Med Eng* **2016**,  
612 5162394 (2016).

613 19. Jacob, L. *et al.* Conserved meningeal lymphatic drainage circuits in mice and humans. *J*  
614 *Exp Med* **219**, (2022).

615 20. Hu, L., Wickline, S. A. & Hood, J. L. Magnetic resonance imaging of melanoma exosomes  
616 in lymph nodes. *Magn Reson Med* **74**, 266–271 (2015).

617 21. Oshiro, H. *et al.* Retrograde Lymphatic Spread of Esophageal Cancer: A Case Report.  
618 *Medicine* **94**, e1139 (2015).

619 22. Joshi, A. S., Singh, V., Gahane, A. & Thakur, A. K. Biodegradable Nanoparticles  
620 Containing Mechanism Based Peptide Inhibitors Reduce Polyglutamine Aggregation in  
621 Cell Models and Alleviate Motor Symptoms in a Drosophila Model of Huntington’s  
622 Disease. *ACS Chem Neurosci* **10**, 1603–1614 (2019).

623 23. Dominy, S. S. *et al.* Porphyromonas gingivalis in Alzheimer's disease brains: Evidence for  
624 disease causation and treatment with small-molecule inhibitors. *Sci Adv* **5**, eaau3333  
625 (2019).

626 24. Ahmadi Badi, S. *et al.* Microbiota-Derived Extracellular Vesicles as New Systemic  
627 Regulators. *Front Microbiol* **8**, 1610 (2017).

628 25. Grauer, O. *et al.* Combined intracavitary thermotherapy with iron oxide nanoparticles  
629 and radiotherapy as local treatment modality in recurrent glioblastoma patients. *J  
630 Neurooncol* **141**, 83–94 (2019).

631 26. Da Mesquita, S. *et al.* Functional aspects of meningeal lymphatics in ageing and  
632 Alzheimer's disease. *Nature* **560**, 185–191 (2018).

633 27. Ahn, J. H. *et al.* Meningeal lymphatic vessels at the skull base drain cerebrospinal fluid.  
634 *Nature* **572**, 62–66 (2019).

635

## 636 Acknowledgements

637 We thank Sergio Alvarez for his collaboration with electroporation equipment. The  
638 authors acknowledge Wilda Olivares, Andrés Rodriguez, Pablo Santoro, Ignacio  
639 Wichmann, Rocío Bustos, Leticia Gonzalez, Miguel Urrutia, Mauricio Cuello, and Flavia  
640 Zacconi for comments and assistance. This study was supported by ANID  
641 BECAS/DOCTORADO NACIONAL 21211334; ANID - Millennium Science Initiative  
642 Program - ICN2021\_004, ANID – FONDECYTs 1220922, 1231773 and 1211482;  
643 CONICYT-FONDAP 15130011, FONDEQUIP NTA (EQM160157), and FONDEQUIP  
644 SEM (EQM170111).

## 645 Author contributions

646 H.M.R.Z. and I.P. conceived the study. H.M.R.Z., I.P., E.S.H. A.H.C., M.J.K., C.P.Y.,  
647 J.E.O., A.N.T., P.V.B., and M.E.A. designed the experiments. H.M.R.Z., I.P., E.S.H.,  
648 P.J.G., A.N.T., P.V.B., V.A.C., E.A.M., and A.R. performed preparation and  
649 characterization of nanoparticles. H.M.R.Z., C.P.Y., and C.M. conducted mouse  
650 experiments. D.S. performed histological analysis and immunohistochemistry

651 techniques. J.E.O. conducted cytotoxicity analysis. All authors participated in data  
652 analysis. H.M.R.Z. wrote the paper and all the authors contributed to its editing.

653 **Data availability**

654 The data that support the findings of this study are available from the corresponding  
655 author upon reasonable request.

656 **Competing interests**

657 The authors declare no competing interests.

658 **Corresponding author**

659 Correspondence and requests for materials should be addressed to Héctor M. Ramos-  
660 Zaldívar. Primary email: [hmramos@uc.cl](mailto:hmramos@uc.cl).

661

662

663

664

665

666


667

668

669

670


671 **Figures and figure legends**



672


673

**d**



674

675



676


677

**e**




678

679



680

681 **Fig. 1: Characterization of nanoparticles.** **a**, STEM visualization of SPIONs; size distribution and zeta potential measured by DLS. **b**, STEM visualization of exosomes with and without SPIONs labeling; size distribution and zeta potential measured by DLS. **c**, Western blot of EV markers EEA1 and TSG101 on exosomes from the B16F10 melanoma cell line. Control was performed using a cellular extract from the B16F10 cell line. Quantification of EEA1 and TSG101 with respect to control is shown. **d**, STEM visualization of gold nanorods; size distribution measured by NTA and zeta potential determined by DLS. **e**, STEM visualization of Chinese ink; size distribution and zeta potential measured by DLS.



706 **Fig. 2: Directional flow analysis by MRI of SPIONs and SPION-labeled exosomes through the**  
707 **cervical and meningeal lymphatic system. a, Retrograde Directional Analysis:** Brain images  
708 **reveal the detection of nanoparticles in this region 30 minutes after injection into the deep**  
709 **cervical lymph node (n=3), particularly evident in the T2\* map (yellow arrowheads).** These two  
710 **conditions were compared to control mice with no injected solutions (n=3). b, Anterograde**  
711 **Directional Analysis:** Neck images reveal the detection of nanoparticles in this region 30 minutes  
712 **after injection into the cisterna magna (n=3), particularly evident in the T2\* map (yellow arrowheads).**  
713 **These two conditions were compared to control mice with no injected solutions (n=3).**


714

## Histological Brain Analysis



715

**a** **Injection site**



717


718

719

720

721

722




723

**b** **Injection site**

**Post-mortem**

**Chinese ink**



725

726

727

728

729

730

731

**Fig. 3: Retrograde directional flow analysis by brain histology after *post-mortem* nanoparticle administration into the deep cervical lymph node. a**, Gold nanorods were identified by the Gold Enhancement technique in the olfactory bulb, the brain parenchyma, and the meningeal lymphatic vessels (red arrows) (n=3). **b**, Chinese ink nanoparticles stained the meningeal lymphatic vessels, the brain parenchyma, and the third ventricle wall (red arrows) (n=3).

737

## Histological Brain Analysis



738

a

Injection site







*In vivo*

Gold Nanorods

739

740



741

742

743

744

745

b

Injection site






*In vivo*

Chinese ink

746

747

748



749

750

751

752

753

**Fig. 4: Retrograde directional flow analysis by brain histology after *in vivo* nanoparticle administration into the deep cervical lymph node. a**, Combined Gold Enhancement and anti-LYVE-1 immunohistochemistry showed gold nanorods within meningeal lymphatic vessels (red arrows) and the brain parenchyma (yellow arrows), with no staining within cerebral arteries (n=3). **b**, Meningeal lymphatic vessels stained with anti-LYVE-1 immunohistochemistry and colocalized with Chinese ink nanoparticles (red arrows). Chinese ink was also identified in the brain parenchyma (yellow arrows) (n=4). LYVE-1: lymphatic vessel endothelial hyaluronan receptor-1.

761

762

## Histological Neck Analysis





763

**a**

Injection site  
*Post-mortem*  
Gold Nanorods

764



765

766

767

768

769





770

**b**

Injection site  
*Post-mortem*  
Chinese ink

771

772



773

774

775

776

**Fig. 5: Anterograde directional flow analysis by brain histology after post-mortem nanoparticle administration into the cisterna magna.** **a**, Gold Enhancement showed staining of the cervical spinal cord (red arrow), its surrounding subdural space (yellow arrow) and associated peripheral nerves (green arrow). Gold nanoparticles were also detected in cervical lymphatic vessels and connective tissue (black arrows) (n=3). **b**, Chinese ink nanoparticles were identified in cervical lymphatic vessels, connective tissue, as well as the cervical spinal cord and its surrounding subdural space (indicated by red arrows) (n=3). SC: spinal cord.

784

785

786

## Histological Neck Analysis




787

**a**

Injection site  
*In vivo*  
Gold Nanorods

788

789



790

791

792

793

794

795

**b**

Injection site  
*In vivo*  
Chinese ink

796

797


798

799

800

801

802



803


**Fig. 6: Anterograde directional flow analysis by brain histology after *in vivo* nanoparticle administration into the cisterna magna. a, Gold Enhancement showed staining of lymphatic vessels in the cervical region (red arrows) (n=3). b, Chinese ink nanoparticles were identified in the cervical lymphatic vessels (red arrows), the subarachnoid space (black arrows), as well as the cervical spinal cord (yellow arrow), peripheral nerves (orange arrow), and connective tissue (blue arrows) (n=3).**

809

810 **Supplementary figures**


811

812



**Supplementary Fig. S1: Retrograde directional flow analysis after *in vivo* administration of SPIONs into the deep cervical lymph node. a**, Perls' Prussian Blue shows staining of lymphatic vessels of the head (red arrows), including the meningeal lymphatic vessels, as well as connective tissue (yellow arrow) (n=3). **b**, SPIONs were also identified within lymphatic vessels of the neck (red arrows) (n=3). SPIONs: superparamagnetic iron oxide nanoparticles.





881

882

883

884

885

886

887

888 **Supplementary Fig. S4: Anterograde directional flow analysis after *in vivo* administration of**  
889 **SPIONs into the cisterna magna. a**, Perls' Prussian Blue shows staining of cervical lymphatic  
890 **vessels (red arrows) (n=3). b**, SPIONs were identified within ventricular spaces of the brain (n=3).  
891 **SPIONs: superparamagnetic iron oxide nanoparticles.**

892

